Previous studies have shown that hippocampal GSK-3β activity significantly increased in CMS-treated rats or patients with major depressive disorders [28, 29], and antidepressant behavior was observed in CMS rats treated with GSK-3β inhibitors [28]. Here, GSK3B is linked to major depressive disorder.